西罗莫司对淋巴管肌瘤病患者肺囊肿及肺功能的影响:长期随访观察性研究
回顾性纳入2001年5月至2018年6月确诊的73例女性淋巴管肌瘤病患者,其中39例(53.4%)接受西罗莫司治疗,比较基线与随访CT肺囊肿评分及肺功能。西罗莫司治疗后定量与定性囊肿评分较基线显著增加,但开始治疗时与末次随访间无显著差异,DLCO显著升高,囊肿评分与肺功能显著相关。
要点
- 西罗莫司治疗后肺囊肿体积在部分患者中缩小,定量分析显示治疗开始与末次CT间无显著差异。
- 西罗莫司治疗后DLCO显著升高,肺功能改善或维持。
- 胸部CT可作为评估和监测淋巴管肌瘤病肺囊肿的影像生物标志物。
核心结论
- 淋巴管肌瘤病患者从西罗莫司治疗中获益;CT可能是评估和监测肺囊肿的有用影像生物标志物。
研究设计与样本
- 回顾性研究,纳入2001年5月至2018年6月确诊的73例女性淋巴管肌瘤病患者,其中39例(53.4%)接受西罗莫司治疗;对肺囊肿进行定量和定性CT评分,并与肺功能检查结果比较。
关键影像表现/征象
- 定量和定性分析均显示,肺囊肿评分从基线至开始西罗莫司后随访显著增加,从基线至末次随访也显著增加(均p<0.05)。
- 在接受西罗莫司治疗的患者中,开始西罗莫司时与末次随访的评分无显著差异。
- 定性分析显示,西罗莫司治疗后共有15.8%至21.1%的患者肺囊肿体积缩小。
诊断标准与关键数值
- 定量和定性CT肺囊肿评分与各时间点肺功能检查显著相关(相关系数r为-0.383至0.935;均p<0.001)。
- 西罗莫司治疗后DLCO显著增加。
临床应用与阅片要点
- 胸部CT可用于评估和监测淋巴管肌瘤病患者的肺囊肿变化。
- 阅片时可结合定量与定性囊肿评分,并参考肺功能检查结果综合评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether sirolimus has beneficial effects on lymphangioleiomyomatosis (LAM) lung cysts in CT with long-term follow-up (FU) and to investigate whether CT is an appropriate imaging biomarker to monitor and evaluate LAM progression.
METHODS: In this retrospective study, 73 female patients diagnosed with definite LAM between May 2001 and June 2018 were included. Among these, 39 (53.4%) were treated with sirolimus. Quantitative and qualitative CT scoring for lung cysts (CS) were performed and compared between time points (baseline vs. FU at starting sirolimus, baseline vs. last FU, and FU at starting sirolimus vs. last FU for patients treated with sirolimus; baseline vs. last FU for patients without sirolimus). The correlation between CS at each time point and pulmonary function tests (PFTs) at each time point in the patients treated with sirolimus was also investigated. The quantitative and qualitative analyses and PFT results were compared between time points.
RESULTS: In both quantitative and qualitative analyses, CS significantly increased from baseline to FU after starting sirolimus, and from baseline to last FU (all p < 0.05), whereas there was no significant difference between scores at the start of sirolimus vs. last in the patients treated with sirolimus. After sirolimus treatment, diffusing capacity for carbon monoxide (DLCO) was significantly increased. There were significant correlations between CS at each time point and PFT (correlation coefficient [r], - 0.383-0.935; all p < 0.001).
CONCLUSION: Patients with LAM benefited from sirolimus. CT could be a useful imaging biomarker for evaluating and monitoring lung cysts in LAM.
KEY POINTS: • Qualitative analysis showed a total of 15.8% to 21.1% of patients had a reduced lung cyst volume after sirolimus treatment, and in quantitative analysis, there was no significant difference in lung cyst volume between CT at the start of sirolimus therapy and the last CT. • Pulmonary function was also improved or maintained after sirolimus treatment. • Chest CT could be a useful imaging biomarker for evaluating and monitoring lung cysts in patients with lymphangioleiomyomatosis.
引用
- Kim C, Do KH, Cha J, et al. Effects of sirolimus in lymphangioleiomyomatosis patients on lung cysts and pulmonary function: long-term follow-up observational study. Eur Radiol. 2019. PMID: 31471750. doi:10.1007/s00330-019-06412-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。